174 related articles for article (PubMed ID: 25312395)
1. Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents.
Kumar V; Khan S; Gupta P; Rastogi N; Mishra DP; Ahmed S; Siddiqi MI
J Comput Aided Mol Des; 2014 Dec; 28(12):1247-56. PubMed ID: 25312395
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and Procaterol Combination in Gastric Cancer? Targeting Checkpoint Kinase 1 for Cancer Drug Discovery and Repurposing by an Integrated Computational and Experimental Approach.
Giridhara Prema S; Chandrasekaran J; Kanekar S; George M; Prasad TSK; Raju R; Dagamajalu S; Balaya RDA
OMICS; 2024 Jan; 28(1):8-23. PubMed ID: 38190280
[TBL] [Abstract][Full Text] [Related]
3. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
4. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
5. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
Zenvirt S; Kravchenko-Balasha N; Levitzki A
Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
[TBL] [Abstract][Full Text] [Related]
6. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Xiao Z; Xue J; Sowin TJ; Zhang H
Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint kinase inhibitors: a review of the patent literature.
Janetka JW; Ashwell S
Expert Opin Ther Pat; 2009 Feb; 19(2):165-97. PubMed ID: 19441917
[TBL] [Abstract][Full Text] [Related]
8. Chk1 inhibitors for novel cancer treatment.
Tao ZF; Lin NH
Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
[TBL] [Abstract][Full Text] [Related]
9. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
10. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
[TBL] [Abstract][Full Text] [Related]
11. CHK1 kinase inhibition: identification of allosteric hits using MD simulations, pharmacophore modeling, docking and MM-PBSA calculations.
Al-Shar'i N; Musleh SS
Mol Divers; 2022 Apr; 26(2):903-921. PubMed ID: 33686514
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells.
Bryant C; Scriven K; Massey AJ
Mol Cancer; 2014 Jun; 13():147. PubMed ID: 24913641
[TBL] [Abstract][Full Text] [Related]
13. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells.
Sahu RP; Batra S; Srivastava SK
Br J Cancer; 2009 May; 100(9):1425-33. PubMed ID: 19401701
[TBL] [Abstract][Full Text] [Related]
14. Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.
Kawasumi M; Bradner JE; Tolliday N; Thibodeau R; Sloan H; Brummond KM; Nghiem P
Cancer Res; 2014 Dec; 74(24):7534-45. PubMed ID: 25336189
[TBL] [Abstract][Full Text] [Related]
15. γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.
Rawlinson R; Massey AJ
BMC Cancer; 2014 Jul; 14():483. PubMed ID: 24996846
[TBL] [Abstract][Full Text] [Related]
16. Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.
Chen XM; Lu T; Lu S; Li HF; Yuan HL; Ran T; Liu HC; Chen YD
J Mol Model; 2010 Jul; 16(7):1195-204. PubMed ID: 20020310
[TBL] [Abstract][Full Text] [Related]
17. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.
Jackson JR; Gilmartin A; Imburgia C; Winkler JD; Marshall LA; Roshak A
Cancer Res; 2000 Feb; 60(3):566-72. PubMed ID: 10676638
[TBL] [Abstract][Full Text] [Related]
18. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Yin MB; Guo B; Vanhoefer U; Azrak RG; Minderman H; Frank C; Wrzosek C; Slocum HK; Rustum YM
Mol Pharmacol; 2000 Mar; 57(3):453-9. PubMed ID: 10692484
[TBL] [Abstract][Full Text] [Related]
19. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
[TBL] [Abstract][Full Text] [Related]
20. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.
Xiao Z; Xue J; Gu WZ; Bui M; Li G; Tao ZF; Lin NH; Sowin TJ; Zhang H
Biomarkers; 2008 Sep; 13(6):579-96. PubMed ID: 18671143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
